Table 1 Patient Characteristics
|  | All (n = 101) | Dacomitinib (n = 31) | Afatinib(n = 70) | p-value |
|---|---|---|---|---|
Age ≥ 65 years | 53 (52.5) | 19 (61.3) | 34 (48.6) | 0.240 |
Male | 41 (40.6) | 10 (32.3) | 31 (44.3) | 0.257 |
Smoking | 38 (37.6) | 10 (32.3) | 28 (40.0) | 0.461 |
ECOG PS ≥ 2 | 3 (3.0) | 1 (3.2) | 2 (2.9) | 1.000 |
EGFR mutation | Â | Â | Â | 0.293 |
Del 19 | 37 (36.6) | 9 (29.0) | 28 (40.0) | Â |
L858R | 64 (63.4) | 22 (71.0) | 42 (60.0) | Â |
Metastasis organ | Â | Â | Â | Â |
Lung metastasis | 34 (33.7) | 7 (22.6) | 27 (38.6) | 0.119 |
LN metastasis | 79 (78.2) | 24 (77.4) | 55 (78.6) | 0.897 |
Pleural metastasis | 46 (45.5) | 16 (51.6) | 30 (42.9) | 0.417 |
Liver metastasis | 12 (11.9) | 5 (16.1) | 7 (10.0) | 0.382 |
Bone Metastasis | 39 (38.6) | 13 (41.9) | 26 (37.1) | 0.649 |
CNS metastasis | 13 (12.9) | 1 (3.2) | 12 (17.1) | 0.061 |
Adrenal metastasis | 5 (5.0) | 2 (6.5) | 3 (4.3) | 0.641 |
EGFR-TKI Treatment | Â | Â | Â | Â |
Standard dose | 29 (28.7) | 5 (16.1) | 24 (34.3) | 0.064 |
Adjust dose | 12 (11.9) | 4 (12.9) | 8 (11.4) | 1.000 |
Discontinuation | 7 (6.9) | 4 (12.9) | 3 (4.3) | 0.118 |
Local radiation therapy | 29 (28.7) | 12 (38.7) | 17 (24.3) | 0.147 |
Response | Â | Â | Â | 0.522 |
Partial response | 85 (84.2) | 25 (80.6) | 60 (85.7) | Â |
Stable disease | 16 (15.8) | 6 (19.4) | 10 (14.3) | Â |